All News

Your daily dose of the clinical news you may have missed.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.

Dhiren Patel, PharmD, and Robert Busch, MD, present an overview of chronic kidney disease (CKD) and how it may impact a patient.

Clinicians must remember the point of vaccines was not to prevent infection, but to decrease severity of illness, says infectious disease specialist Gopi Patel, MD.

The FDA cites insufficient evidence to show the products would be beneficial for adults switching to vaping from combustible tobacco products or quitting.

Gopi Patel, MD, emphasizes the importance of promoting vaccination and infection prevention measures among fellow clinicians, as well as patients, this season.

Your daily dose of the clinical news you may have missed.

IDWeek chair Heather Yun, MD, observed that "primary care clinicians are out in front of all things," and that job is big and it's hard.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

IDWeek 2023 chair Yun points to climate change and other human-driven devastation of the biosphere as the global threats that will cause disease at local levels.

IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

IDWeek 2023. Results highlight potential impact of influenza vaccination in reducing CV, respiratory, and other complications in adults aged ≥65 years with underlying chronic conditions.

The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.